Epigenetic Landscape in Cancer: From Biomarker Identification to Drug Discovery
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 6352
Special Issue Editors
Interests: tumor microenvironment; epigenetics; immunotherapy; drug discovery; signal transduction
Special Issues, Collections and Topics in MDPI journals
Interests: epigenetics; molecular biology; cancer; RNA modifications; drug discovery; genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Epigenetics represents the study of the chromatin context that regulates and perpetuates different gene activities in the presence of the same DNA sequence. The intrinsic relationship between DNA, proteins and RNAs that regulates gene function is also controlled by several environmental factors and is transmissible from one generation to the next. In recent years, epi-mutations, by breaking down specific gene regulatory mechanisms, have been highlighted to play a critical role in contributing to the hallmarks of cancer. Since the alteration of chromatin machinery is a common occurrence in different types of malignancies, it can become a valid target for their eradication, including those tumors resistant to conventional therapy, such as metastatic cancers. Additionally, epigenetic alterations are already being incorporated as valuable biomarker candidates, and some epigenetic biomarkers have been approved by the US Food and Drug Administration (FDA) for diagnosis, prognosis, or response to cancer therapy. Therefore, identifying and exploring new epigenetic targets as well as biomarkers will represent a desirable milestone in the next decade. The proposed Special Issue aims to address all the aspects of epigenetics applied to the identification of new biomarkers and the discovery of new drugs for the treatment of both solid and hematological cancers, with reference to the exploitation of new knowledge acquired for development of new targeted personalized therapies.
Dr. Mariarosaria Conte
Dr. Nunzio Del Gaudio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- epigenetics
- biomarker
- drug discovery
- targeted therapy
- chromatin
- gene function
